[Skip to Content]
[Skip to Content Landing]
Observation
November 2018

Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib

Author Affiliations
  • 1Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, Maryland
  • 2National Heart, Lung, and Blood Institute, Bethesda, Maryland
JAMA Dermatol. 2018;154(11):1357-1358. doi:10.1001/jamadermatol.2018.2927

Severe aplastic anemia (SAA) is a rare disease in which the bone marrow cannot produce adequate supplies of cells. A more recent and curative approach to SAA includes allogenic hematopoietic stem-cell transplantation (allo-HCT). Graft-vs-host disease (GVHD) is one of the most frequent complications of allo-HCT and is associated with high morbidity and mortality.1 In both its acute and chronic subtypes, GVHD manifests in multiple organs. Chronic GVHD affects 30% to 70% of patients, with an onset of 4 to 6 months after transplant.2

×